Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Partners Beckley Psytech and atai Life Sciences (NASDAQ:ATAI) have jointly announced positive initial results from a Phase 2a study of Beckley’s novel formulation of 5-MeO-DMT in Treatment Resistant Depression (TRD.)
BPL-003 is a synthetic and patent-protected benzoate salt formulation of 5-MeO-DMT (aka mebufotenin) designed for intranasal administration. The open-label study assessed safety, tolerability and efficacy of the compound at a single 10mg dose, alongside psychological support, in patients with moderate-to-severe TRD (who withdrew from concomitant antidepressants.) Learn more.
Providers at Utah’s two largest healthcare systems may now treat patients with psilocybin and MDMA as part of a pilot program created by a proposal-turned-law that will take effect as early as May 1, 2024.
The program, open to providers at the University of Utah Health and Intermountain Health, will last three years. Next, the Legislature will decide whether or not to resume it. Learn more.
Elon Musk once again made the case for using psychedelics. In a new interview with former CNN anchor Don Lemon, the business magnate said prescription ketamine has helped him with occasional depressive episodes. He also suggested that taking the ketamine has also been beneficial for investors in his companies.
The Tesla (NASDAQ:TSLA) and SpaceX chief executive says he takes “a small amount once every other week,” and sometimes less frequently, to treat the “chemical tides” that can trigger his depression. “Ketamine is helpful for getting one out of a negative frame of mind,” Musk told Lemon. Keep reading.
Prosecutors in Virginia are probing whether Facebook-parent Meta’s social media platforms Facebook and Instagram are facilitating and profiting from the illegal sale of drugs, according to a Saturday Wall Street Journal report.
Led by Assistant U.S. Attorney Randy Ramseyer, the investigation includes delving into whether Meta (NASDAQ:META) failed to adequately remove drug-related content from its platforms. Read more.
Welcome to a new episode of the Benzinga Psychedelics Podcast where we're joined by Robert Barrow, CEO of Mind Medicine (MindMed) (NASDAQ:MNMD), which has taken the development of LSD-based therapy to new heights. The biopharma company recently obtained a “breakthrough therapy” designation for the treatment of generalized anxiety from the U.S. Food and Drug Administration (FDA.)
Find out more and listen here.
See Also: Prior Edition Of ‘Psyched’
AdvisorShares Psychedelics ETF (NYSE:PSIL) opened Monday, March 25 at $1.45, following openings at $1.50, $1.65 and $1.58 (March 18, 11 and 4, respectively.)
On Thursday, March 28, it closed at $1.49, following prior closings at $1.44, $1.53 and $1.64 (March 22, 15 and 8, respectively.)
The week's highest within open market hours was $1.49, vs. prior highest points $1.55, $1.65 and $1.78.
Week's lowest (open market hours) was $1.42, vs. prior lowest points $1.41, $1.46 and $1.44.
Stock trading numbers above according to Benzinga Pro, our all-the-information-you-need streaming platform helping you invest smarter – Come join us and see for yourself!
Posted In: ATAI CMND CMPS DRUG ENVB GHRS IXHL LSDI MDXXF META MNMD PSIL SILO TSLA